Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$8.44 USD
-0.27 (-3.10%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $8.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 81 - 100 ( 364 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
IVI, KNIH, CEPI - INO to Conduct COVID-19 Vaccine Trial in South Korea
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Advances Into Phase 1 Testing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presentations at ASCCP Annual Meeting in HSIL Underscore VGX-3100 Efficacy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 2 Data in HPV-Associated Vulvar Dysplasia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive HPV-Associated Anal Dysplasia Phase 2 Interim Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim Phase 2 Results in HSIL - VGX-3100 Shows Consistency
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Department of Defense Grant to Rapidly Produce COVID-19 Vaccine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q and full-Year 2019 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Trials Progress, Ample Grant Funding for COVID-19 - Reports 4Q19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vaccine Development Timeline Accelerated; Positive Preclinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vaccine to Enter Clinical Testing Next Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Crisis Update- Infections Moving West
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department